Afatinib was evaluated in the LUX-Lung 6 trial as a first-line treatment in Asian patients with epidermal growth factor receptor mutation-positive advanced NSCLC

A joint program between Bionomics Ltd., of Thebarton, Australia, and the Co-operative Research Centre for Cancer Therapeutics reached a proof-of-concept milestone for Ctx-0357927, an inhibitor of vascular growth factor receptor 3

The FDA approved Tarceva (erlotinib) tablets for first-line treatment of metastatic non-small-cell lung cancer characterized by tumors with epidermal growth factor receptor-activating mutations

Ltd., said Harvard Medical School presented data at the Association for Research in Vision and Ophthalmology conference in Seattle showing a major link between vascular endothelial growth factor (VEGF)-C levels and age-related macular degeneration (AMD) and that assessment of Opthea's drug development candidate, VGX-300 (a soluble form of VEGF receptor-3 that blocks VEGF-C and VEGF-D) in animal models of wet AMD confirmed its potential as a new therapy for the disease

TrkA kinase is a high-affinity receptor for nerve growth factor, which is implicated in the pathology of pruritus through its association with peripheral sensory neurons...Increased local concentrations of nerve growth factor – as occurs in psoriasis – act via TrkA, resulting in the sensitization of sensory neurons

C-Cure (formerly C3BS-CQR-1) comprises an infusion of autologous bone marrow-derived mesenchymal stem cells, which are reprogrammed ex vivo using a complex cocktail of growth factors, to become "cardiopoietic" or cardiac progenitor cells

Among its assets were OSI-906, an insulin-like growth factor-1 inhibitor in Phase III for adrenocortical carcinoma and Phase II for ovarian cancer

ErbB1, better known as epidermal growth factor receptor, or EGFR, is the target of drugs such as Tarceva (erlotinib, Roche AG and Astellas Pharma Inc.), Iressa (gefitinib, AstraZeneca plc.), Vectibix (panitumumab, Amgen Inc.) and Erbitux (cetuximab, Eli Lilly and Co.) Roche drugs Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) target ErbB2, which also goes by HER2/neu

TrkA kinase is a high-affinity receptor for nerve growth factor, which is implicated in the pathology of pruritus through its association with peripheral sensory neurons...Increased local concentrations of nerve growth factor – as occurs in psoriasis – act via TrkA, resulting in the sensitization of sensory neurons

Ltd., said Harvard Medical School presented data at the Association for Research in Vision and Ophthalmology conference in Seattle showing a major link between vascular endothelial growth factor (VEGF)-C levels and age-related macular degeneration (AMD) and that assessment of Opthea's drug development candidate, VGX-300 (a soluble form of VEGF receptor-3 that blocks VEGF-C and VEGF-D) in animal models of wet AMD confirmed its potential as a new therapy for the disease

C-Cure (formerly C3BS-CQR-1) comprises an infusion of autologous bone marrow-derived mesenchymal stem cells which are reprogrammed ex vivo, using a complex cocktail of growth factors, to become 'cardiopoietic' or cardiac progenitor cells

In the agreement, Symphogen out-licensed its lead product, Sym004, a Phase II program targeting epidermal growth factor receptor (EGFR

Both involve Ambrx's protein medicinal chemistry technology, one targeting fibroblast growth factor 21 for Type II diabetes and the other focused on the relaxin hormone for the treatment of heart failure...Among the other ADC players is Celldex Therapeutics Inc., which in February raised $90 million plus $12.7 million for overallotments in a public offering to advance rindopepimut, its immunotherapy targeting epidermal growth factor variant III, in a registration study in front-line glioblastoma

In exchange for rights to antibodies targeting platelet-derived growth factor receptors, Regeneron agreed to pay Sanofi $10 million up front, up to $40 million in development milestones and royalties on sales

Cardium Therapeutics Inc., of San Diego, said the April 2013 issue of Molecular Therapy published a paper, titled "Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of Coronary Collateral Development by Angiogenic Growth Factors

In the agreement, Symphogen out-licensed its lead product, Sym004, a Phase II program targeting epidermal growth factor receptor (EGFR

The meeting comes on the heels of a request for proposals from the Biomedical Advanced Research and Development Authority (BARDA) for 2.8 million courses of a granulocyte colony-stimulating factor (G-CSF) such as Neupogen. (See BioWorld Today, March 15, 2013.) That Neupogen, as a leukocyte growth factor (LGF), has shown efficacy in treating radiation-induced myelosuppression is hardly surprising

In the current set of experiments, they discovered that antibodies to the receptor for the growth factor G-CSF caused bone marrow cells to turn into brain cells

In a second program, a class of compounds that target two different growth factor signaling pathways in oncology is in the late lead optimization phase